10-Q · May 5, 2026
Neurocrine Biosciences reported a strong Q1 2026 with revenue of $814.5 million, an increase of 42.3% year-over-year, driven primarily by net product sales growth from INGREZZA and CRENESSITY. The company reported an…
Earnings analysis · 10-Q
NBIX earnings analysis
Filed November 2, 2026 · Our reading of the company's report
The latest report
Neurocrine delivered strong Q3 momentum, with revenue of $1.119 billion and non-GAAP diluted EPS of $3.29, up materially from both Q2 2026 and Q3 2025. Growth is supported by a broader three-product portfolio following…
Read full summary
Neurocrine delivered strong Q3 momentum, with revenue of $1.119 billion and non-GAAP diluted EPS of $3.29, up materially from both Q2 2026 and Q3 2025. Growth is supported by a broader three-product portfolio following the Soleno acquisition, although the supplied 10-Q excerpt does not provide segment revenue, margin, cash-flow, or balance-sheet figures. The principal incremental risks are VYKAT XR safety scrutiny, Soleno integration and litigation exposure, concentrated distribution, and intensifying drug-pricing pressure.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $3.29
What stood out
-
Revenue accelerated to $1.119 billion
Q3 revenue was $1.119 billion, up approximately $160 million, or 16.7%, from $959 million in Q2 2026 and up approximately $324 million, or 40.8%, from $795 million in Q3 2025.
-
EPS materially exceeded prior periods
Reported diluted EPS was $3.29 versus $1.39 in Q2 2026 and $2.04 in Q3 2025, increases of $1.90 and $1.25, respectively. The supplied earnings data identifies $3.29 as non-GAAP diluted EPS.
-
Portfolio broadened to three products
The company now has three commercial products: INGREZZA, CRENESSITY and VYKAT XR; VYKAT XR was obtained through the Soleno acquisition completed in the second quarter of 2026.
-
Share repurchases continued
As of September 30, 2026, the company had repurchased 618,197 shares during Q3, including 472,398 shares in September at an average price of $147.27; $174.240 million remained available under the repurchase program.
-
Liquidity supported by undrawn facility
The company entered into a five-year, $1.0 billion senior secured revolving credit facility in May 2026, and no amounts were outstanding as of September 30, 2026, preserving borrowing capacity.
What to watch
-
VYKAT XR safety scrutiny increased
VYKAT XR faces emerging safety and commercialization risk: in September 2026, the FDA identified fluid retention as a potential safety signal and stated that it was evaluating the need for regulatory action. In August 2026, patient advocacy organizations also cited serious adverse-event reports and called for increased awareness and monitoring.
-
Soleno integration and litigation risk
The Soleno acquisition creates integration and litigation exposure. A putative securities class action was filed on March 6, 2026, covering purchasers during March 26, 2025 through November 4, 2025; the company warns that adverse resolution could result in substantial costs, damages or indemnification obligations.
-
Drug-pricing policy remains a headwind
Government pricing and reimbursement pressure could increase: the GLOBE Model is scheduled to begin in January 2027, while INGREZZA remains exempt from Medicare negotiation selection only until 2027, with negotiated pricing potentially applying in 2029 if selected.
-
Concentrated distribution exposure
Customer concentration is substantial: four customers across the commercial-product distribution arrangements represent over 90% of total gross product sales, and CRENESSITY and VYKAT XR each rely on one specialty pharmacy provider.
-
INGREZZA DOJ investigation unresolved
The company received a DOJ civil investigative demand in August 2025 seeking documents and information related to sales and marketing of INGREZZA; the filing states that the company is cooperating, but the timing and outcome remain uncertain.
-
Supply chain and tariff exposure
The company depends on third-party manufacturing and has foreign exposure: it currently has no manufacturing capabilities, relies on third parties, and states that tariffs on pharmaceutical imports could increase production and research costs.
Management's outlook
The supplied 10-Q excerpt does not include a quantitative company-wide outlook. The prior 8-K disclosed raised full-year 2026 INGREZZA net product sales guidance to $2.900-$2.925 billion from $2.825-$2.875 billion, but that guidance is not attributed to the supplied 10-Q excerpt.
Earlier filings 4
10-K · February 11, 2026
Neurocrine Biosciences delivered strong revenue growth in 2025, driven by the introduction of its new drug CRENESSITY and sustained performance from INGREZZA, despite economic pressures impacting margins and profits.…
10-Q · October 28, 2025
Neurocrine Biosciences reported impressive Q3 2025 results with revenue up 27.3% year-over-year to $795 million, significantly exceeding estimates. EPS increased to $2.04, marking a 64.5% rise compared to the previous…
10-Q · July 30, 2025
Neurocrine Biosciences delivered strong financial results for Q2 2025 with revenues of $688 million, surpassing estimates by 5.57%, and an impressive EPS of $1.65, which exceeded expectations by 29.92%. Key growth was…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.